About Rare Mutations and Fusions in Lung Cancer
Currently, there are 12 DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
New & Upcoming Events for Rare Mutations
Latest Updates in Rare Mutations
-
Real Progress and Real Gaps: Highlights of the 2026 AACR Disparities Report
I have spent my career focused on the intersection between cancer research and public health. Since joining LUNGevity over a decade ago, it has been nothing short of a privilege to... -
New Treatment Approved for ROS1-positive NSCLC
On July 22, 2026, the US Food and Drug Administration (FDA) announced the approval of zidesamtinib (Jideytro™) to treat patients with locally-advanced or metastatic ROS1-positive... -
Getting to the Bone of the Matter: Bone-Modifying Agents
LUNGevity offers a variety of virtual support groups called ‘meetups’ where survivors and caregivers impacted by lung cancer connect with others who understand the patient...
Sponsors
